Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 97, Issue 6, Pages 650-658
Publisher
Wiley
Online
2015-02-20
DOI
10.1002/cpt.101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions
- (2014) A Tornio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study
- (2014) K E Kristensen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease
- (2014) Cheng Xie et al. Pharmacogenetics and Genomics
- Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding
- (2013) Guillaume Paré et al. CIRCULATION
- Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel
- (2013) M T Holmberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- (2013) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Evaluation of the Inhibitory Effects of Antihypertensive Drugs on Human Carboxylesterase In Vitro
- (2013) Xu Yanjiao et al. Drug Metabolism and Pharmacokinetics
- CES1A −816C as a Genetic Marker to Predict Greater Platelet Clopidogrel Response in Patients with Percutaneous Coronary Intervention
- (2013) Jian-Jun Zou et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- TheCYP2C19*17 variant is not independently associated with clopidogrel response
- (2013) J. P. Lewis et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?
- (2013) S. Casey Laizure et al. PHARMACOTHERAPY
- Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies
- (2012) Young-Hoon Jeong et al. AMERICAN HEART JOURNAL
- Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans
- (2012) E K Tarkiainen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
- (2012) Joshua P. Lewis et al. Pharmacogenetics and Genomics
- Development and validation of an HPLC–MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion
- (2011) Luigi Silvestro et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer
- (2011) Patrick M. Dansette et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
- (2011) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
- (2011) Y. LI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
- (2010) Klaus A. Tiroch et al. AMERICAN HEART JOURNAL
- In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities
- (2010) T. Fukami et al. DRUG METABOLISM AND DISPOSITION
- Carboxylesterase 1 (Ces1): from monocyte marker to major player
- (2010) G. M. Markey JOURNAL OF CLINICAL PATHOLOGY
- Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite
- (2010) Xavier Delavenne et al. JOURNAL OF SEPARATION SCIENCE
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
- (2009) Alain Li-Wan-Po et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel
- (2009) K. Hagihara et al. DRUG METABOLISM AND DISPOSITION
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
- (2009) Alan R. Shuldiner JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
- (2009) Nagy A. Farid et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition
- (2009) Marie Lordkipanidzé et al. THERAPEUTIC DRUG MONITORING
- Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis
- (2008) Hao-Jie Zhu et al. AMERICAN JOURNAL OF HUMAN GENETICS
- The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
- (2008) KA Kim et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants
- (2008) H.-J. Zhu et al. DRUG METABOLISM AND DISPOSITION
- Cytochrome P-450 Polymorphisms and Response to Clopidogrel
- (2008) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
- (2008) Tabassome Simon et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started